Accuray has launched its Synchrony motion tracking and correction technology that is designed to be used with the Radixact System.
The new technology adds intrafraction motion synchronization capabilities to Accuray’s Radixact System to enable real-time tracking, visualization and correction for tumor motion during treatment. The company says that the technology is designed to improve dose accuracy and treatment times when compared to conventional radiation therapy systems.
Synchrony was originally designed to be used with the CyberKnife System and uses continual image guidance to automatically adjust the movement of a beam in synchronization with target volume movement. In the Radixact System, Synchrony helps image tumors that move from bodily processes like respiration and digestion, as well as patient movement. It can also perform fiducial-free tracking for lung indications.
“Adding the Synchrony motion tracking and correction feature to our Radixact System is the natural next step on the system’s product development roadmap. Accuray is committed to delivering product improvements that enable clinicians to optimize their experience and use of our technology long-term,” Birgit Fleurent, chief marketing officer at Accuray, said in a press release. “We expect to begin shipping the Synchrony technology commercially by the end of calendar year 2019.”
The Radixact System has a built-in CT scanner that images before each treatment session to give clinicians information on the shape and location of tumors. Clinicians can also use the technology to automatically synchronize radiation treatment delivery to a moving tumor throughout a treatment session.
“The introduction of Synchrony for this system will enable clinicians to more easily, and efficiently, deliver precise radiation treatments to tumors that move using image-guided, intensity-modulated radiation therapy (IG-IMRT) with target tracking. In my opinion, this has the potential to expand the way the Radixact System is used, as well as the types of patients who are treated with it,” Jennifer Smilowitz, clinical professor at the University of Wisconsin School of Medicine and Public Health and has been involved in the development of the Radixact System, said.
